Abstract Number: 2676 • 2017 ACR/ARHP Annual Meeting
Reduction of Dlco and FVC in Patients with GERD and Systemic Sclerosis
Background/Purpose: Esophageal involvement is common in Systemic Sclerosis (SSc). It is estimated to occur in 70-90% of patients. Esophageal motor dysfunction is characterized by hypotonia…Abstract Number: 2678 • 2017 ACR/ARHP Annual Meeting
Comparison of Scleroderma Associated Isolated Pulmonary Arterial Hypertension and Pulmonary Hypertension with Concomitant Interstitial Lung Disease
Background/Purpose: Relatively little data exist in the literature to characterize the differences between patients with scleroderma-associated isolated pulmonary arterial hypertension (SSc-PAH, WHO Group 1) and…Abstract Number: 2679 • 2017 ACR/ARHP Annual Meeting
Mortality Is Increased in Scleroderma Associated Pulmonary Arterial Hypertension Patients with Younger Age, Lower Systolic Blood Pressure, and Lower Cardiac Index, but Not in Idiopathic Pulmonary Arterial Hypertension
Background/Purpose: Survival in scleroderma associated pulmonary arterial hypertension (SSc-PAH) is known to be significantly worse compared to that in idiopathic pulmonary arterial hypertension (iPAH). However,…Abstract Number: 2687 • 2017 ACR/ARHP Annual Meeting
Characteristic of Pulmonary Arterial Hypertension in Patients with Anti-U1RNP Antibody-Positive-Connective Tissue Diseases Is Determined By the Underlying Disease Rather Than Autoantibody Profile
Background/Purpose: Patients with connective tissue diseases (CTDs) positive for anti-U1RNP antibody (U1) is characterized by overlapping feature of systemic sclerosis (SSc), systemic lupus erythematosus (SLE),…Abstract Number: 105 • 2017 Pediatric Rheumatology Symposium
Isolated Pediatric Pulmonary Capillaritis: A Comprehensive Single-Center Review of Disease Course, Management, and Prognosis
Background/Purpose: Pediatric diffuse alveolar hemorrhage (DAH) is a life-threatening disorder characterized by pulmonary hemorrhage and respiratory insufficiency. Histologically, DAH with capillary inflammation is known as…Abstract Number: 504 • 2016 ACR/ARHP Annual Meeting
Clinical Significance of Multiple Autoantibody Specificities in Rheumatoid Arthritis: The Role of Anti-Citrullinated Alpha-Enolase and Anti-Interferon Inducible Protein 16 Antibodies
Background/Purpose: Anti-cyclic citrullinated peptide (anti-CCP) auto-antibodies (auto-Abs) represent the current gold standard for the diagnosis of rheumatoid arthritis (RA). However, growing evidence suggests that a…Abstract Number: 801 • 2016 ACR/ARHP Annual Meeting
Multi-Tissue Gene Expression Pathway Analysis of Emerging Therapeutics in a TGFβ Dependent Mouse Model of Systemic Sclerosis
Background/Purpose: We have previously investigated the interplay between TGFβ, BMP, VEGF and endothelin in SSc using the TβRIIΔk-fib strain, a transgenic mouse model in…Abstract Number: 826 • 2016 ACR/ARHP Annual Meeting
Exercise Echocardiography Predicts Future Development of Pulmonary Hypertension in a High-Risk Cohort of Scleroderma Patients
Background/Purpose: Pulmonary hypertension (PH) is the leading cause of scleroderma related deaths and is often detected late in the disease course. Early identification of patients…Abstract Number: 835 • 2016 ACR/ARHP Annual Meeting
A Normal Pulmonary Diffusion Capacity Is Rare in Pulmonary Artery Hypertension in Systemic Sclerosis
Background/Purpose: Methods: Results: > 70% (mean 78%) versus 191 patients (94.6%) who had a low DLCO <70% (mean 39%). There was no difference…Abstract Number: 838 • 2016 ACR/ARHP Annual Meeting
Esophageal Dysmotility and Interstitial Lung Disease in Patients with Scleroderma: A Retrospective Study
Background/Purpose: Systemic sclerosis (SSc) is a connective tissue disease with pulmonary involvement seen in 75% of patients and esophageal involvement in 90% of the patients.…Abstract Number: 972 • 2016 ACR/ARHP Annual Meeting
Outcome of the Scleroderma Population “at Risk” to Develop Pulmonary Hypertension in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Cohort Study
ABSTRACT: Background/Purpose: We investigated predictors of outcome, including mortality and cardiopulmonary hospitalizations in the Òat riskÓ group for pulmonary hypertension in PHAROS, a prospective longitudinal…Abstract Number: 973 • 2016 ACR/ARHP Annual Meeting
Clinical Characterization of Patients with World Health Organization Group 2 Pulmonary Hypertension in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Cohort
Background/Purpose: Pulmonary hypertension (PH) is a leading cause of death in patients (pts) with Systemic Sclerosis (SSc). The World Health Organization (WHO) classifies PH into…Abstract Number: 1238 • 2016 ACR/ARHP Annual Meeting
Assessment of Mortality and Healthcare Costs Associated with Systemic Sclerosis with and without Lung Involvement
Background/Purpose: Patients with systemic sclerosis (SSc) are at high risk of developing interstitial lung disease (ILD) and/or pulmonary hypertension (PH). These two lung manifestations are…Abstract Number: 1344 • 2016 ACR/ARHP Annual Meeting
Characteristics, Treatment and Outcome of Severe Pulmonary Hemorrhage Related to Systemic Disease: French Multicentric Study
Background/Purpose: pulmonary hemorrhage (PH) may complicate systemic disease. The main objective of this study was to describe characteristics, treatment and outcome of patients presenting severe…Abstract Number: 1491 • 2016 ACR/ARHP Annual Meeting
M-Ficolin and MAp44 As Potential Markers of Subclinical Cardiovascular Comorbidity; Cardiac Evaluation By Coronary Computer Tomography and Myocardial Deformation of Left Ventricle in Early Rheumatoid Arthritis Patients
Background/Purpose: 79 DMARD-naïve RA patients with a disease duration < 6 months were included from an inception cohort. Clinical variables, plasma- and serum-M-ficolin and MAp44…
ACR Meeting Abstracts